AstraZeneca AZN announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended approving its ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

AstraZeneca (GB:AZN) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...

The adjusted EPS was $2.08 (1 ADR = 2 Common Shares). AstraZeneca’s top business, oncology, increased 19% (up 22% on constant ...

We recently published a list of 10 Cheap NASDAQ Stocks To Invest In Now. In this article, we are going to take a look at ...

(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer.

Tagrisso has been recommended for approval in the European Union for the treatment of adult patients with locally advanced, ...